PSDV pSivida Corp.

1.20
+0.00  (0%)
Previous Close 1.20
Open 1.19
Price To book 3.53
Market Cap 47178463
Shares 39,315,386
Volume 534,546
Short Ratio 2.94
Av. Daily Volume 509,911

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 171113197
  2. 424B5 - Prospectus [Rule 424(b)(5)] 171094129
  3. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 171083576
  4. 8-K - Current report 171079041
  5. 8-K - Current report 17958555

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released December 2015. Second Phase 3 trial data released June 13, 2017 also met endpoint with NDA to be filed late December or early January 2018.
Medidur
Posterior uveitis
CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
Iluvien
Diabetic macular edema

Latest News

  1. pSivida Corp. Announces First Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
  2. ETFs with exposure to pSivida Corp. : October 10, 2017
  3. Biotech Stocks Ignite in the News on Tuesday
  4. pSivida and Nicox Enter Strategic Collaboration Agreement to Develop Sustained Release Drug to Lower Intraocular Pressure in Patients with Glaucoma
  5. Nicox and pSivida enter strategic collaboration agreement to develop sustained release drug to lower intraocular pressure in patients with glaucoma
  6. pSivida Corp. :PSDV-US: Earnings Analysis: Q4, 2017 By the Numbers : October 5, 2017
  7. Earnings Review and Free Research Report: pSivida’s Revenue Surged 52.2%; Net Loss Narrowed
  8. pSivida Partners with Global Pharmaceuticals Company to Develop Sustained Release Formulations of Glaucoma Drugs
  9. pSivida to Present at the Ladenburg Thalmann 2017 Healthcare Conference
  10. ETFs with exposure to pSivida Corp. : September 18, 2017
  11. Earnings Review and Free Research Report: Catalent’s Revenue Grew 16%; Adjusted EPS Jumped 25%
  12. pSivida Corp. :PSDV-US: Earnings Analysis: 2017 By the Numbers : September 15, 2017
  13. Edited Transcript of PSDV earnings conference call or presentation 11-Sep-17 8:30pm GMT
  14. pSivida Corp. Achieves Significant Milestones Throughout FY 2017; Reports Fourth Quarter and Fiscal 2017 Results
  15. Investor Network: pSivida Corp Shs Chess Depository Interests repr 1/40 Sh to Host Earnings Call
  16. pSivida to Present at Rodman & Renshaw Annual Global Investment Conference
  17. Is pSivida Corp (PSDV) Undervalued?
  18. pSivida Corp. to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Monday, September 11th
  19. pSivida to Present at Canaccord Genuity Growth Conference on August 10, 2017

SEC Filings

  1. CT ORDER - Confidential treatment order 171113197
  2. 424B5 - Prospectus [Rule 424(b)(5)] 171094129
  3. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 171083576
  4. 8-K - Current report 171079041
  5. 8-K - Current report 17958555
  6. 8-K - Current report 17942074
  7. 8-K - Current report 17938260
  8. 8-K - Current report 17925129
  9. 8-K - Current report 17907919
  10. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 17872921